$0.01
+0.00%Price chart
Aug 31Sep 8Sep 21Sep 25Oct 2Oct 20Oct 28Nov 4
Key dataNov 4, 2026
Open$0.02
From 52W high−76.26%
Volume125.00
Market cap$2.58M
P/E (TTM)—
P/S (TTM)26.4x
Div yield—
Key dataNov 4, 2026
Open
$0.02
From 52W high
−76.26%
Volume
125.00
Market cap
$2.58M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.9x
P/E (TTM)
—
RSI (14)
52.8
MomentumView details →
1D Return
+0.00%
YTD Return
+5.45%
SummaryUpdated Jun 1, 2026
Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) is a biotechnology company that went public in April 2022, specializing in advanced diagnostic solutions and molecular testing technologies. Founded as a research-focused entity, the company has positioned itself in the rapidly evolving field of precision medicine, where genetic and biochemical analysis plays an increasingly critical role in healthcare decision-making. Currently, Aspire Biopharma remains in the pre-revenue development stage, focusing on developing high-precision diagnostic assays while burning through cash as it works toward commercialization of its testing platforms.
Similar companies
Latest newsMore news →
Aspire Biopharma Holdings, Inc. issued $3,750,000 aggregate principal amount of secured convertible promissory notes to accredited investors for an aggregate purchase price of $3,000,000.87d agoAspire Biopharma Holdings, Inc. shares rose 10.9% on Monday, trading as high as $7.44 and last at $7.23, with volume of 27,396 shares.93d ago